Jiong-Ming Hu
Cardiovascular Disease · Flushing, NYNPI 1932261716
Payments from drug & device makers
Across 599 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- Merck$2K
- Amgen$2K
- Johnson & Johnson$1K
- AstraZeneca$956
- Novartis$918
- plus $7K from 31 others
What the payments were for
- Consulting fees$240%
- Food & beverage$14,60599%
- Education$630%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 57 | $1,649 |
| Merck | 63 | $1,641 |
| Amgen | 54 | $1,561 |
| Johnson & Johnson | 52 | $1,126 |
| AstraZeneca | 48 | $956 |
| Novartis | 45 | $918 |
| Bayer | 33 | $796 |
| Amarin Pharma, Inc. | 35 | $734 |
| Pfizer | 33 | $699 |
| Novo Nordisk | 16 | $639 |
| Lilly USA, LLC | 28 | $588 |
| Esperion Therapeutics, Inc. | 27 | $572 |
| E.r. Squibb & Sons, L.L.C. | 33 | $532 |
| Abbott | 7 | $432 |
| Sanofi-aventis U.S. LLC | 20 | $403 |
| Lundbeck LLC | 8 | $156 |
| Alnylam Pharmaceuticals Inc. | 5 | $150 |
| Biohaven Pharmaceuticals, Inc. | 1 | $125 |
| Xeris Pharmaceuticals, Inc. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 5 | $123 |
| Eisai Inc. | 1 | $115 |
| Medtronic | 3 | $101 |
| Boston Scientific | 3 | $79 |
| Regeneron Healthcare Solutions, Inc. | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $56 |
| Medicomp Inc | 2 | $50 |
| Lexicon Pharmaceuticals, Inc. | 2 | $49 |
| Arbor Pharmaceuticals, Inc. | 3 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Bardy Diagnostics, Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $24 |
| Bridgebio Pharma, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Gilead | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$500
- Repatha$498
- JARDIANCE$374
- Ozempic$362
- Xience Sierra Coronary Stent System$149
- NURTEC ODT$125
- GVOKE HYPOPEN$125
- Leqembi$115
How this compares
$14,692 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 910 | $719,977 |
| XareltoRivaroxaban | 816 | $654,217 |
| VascepaIcosapent Ethyl | 886 | $391,888 |
| JardianceEmpagliflozin | 474 | $378,827 |
| FarxigaDapagliflozin Propanediol | 357 | $313,640 |
| EntrestoSacubitril/Valsartan | 187 | $145,328 |
| MultaqDronedarone Hcl | 110 | $106,564 |
| JanumetSitagliptin Phos/Metformin Hcl | 100 | $95,165 |
| KerendiaFinerenone | 84 | $77,245 |
| Repatha SureclickEvolocumab | 94 | $67,626 |
| RybelsusSemaglutide | 36 | $55,546 |
| JanuviaSitagliptin Phosphate | 59 | $52,197 |
| OpzeluraRuxolitinib Phosphate | 11 | $45,223 |
| MounjaroTirzepatide | 29 | $39,390 |
| Metoprolol Succinate | 2,807 | $22,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $699 | $719,977910 claims |
| Johnson & JohnsonXarelto | $1,126 | $654,217816 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,649 | $394,981488 claims |
| AstraZenecaFarxiga, Lokelma | $956 | $325,856382 claims |
| MerckJanumet, Januvia, Verquvo | $1,641 | $170,062191 claims |
| NovartisEntresto, Diovan | $918 | $162,143218 claims |
| Sanofi-aventis U.S. LLCMultaq | $403 | $106,564110 claims |
| BayerKerendia | $796 | $77,24584 claims |
| Lilly USA, LLCMounjaro, Trulicity | $588 | $58,52249 claims |
| Novo NordiskRybelsus | $639 | $55,54636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Flushing
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
- Sean DonahoeRiverhead$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.